Loading institutional data...
Loading institutional data...
Institutional ownership roughly stable: -0.40% change quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
4/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$470112 FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -15%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $9M covers all $439306 of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2013-02-28 (10-K).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Interest last disclosed in FY2017 (no longer broken out).
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
Where each multiple sits in its own 8-yr range · 31th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 8-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 37.7 | 35.9 | 38.2 | 41.4 | 44.9 | 41.4 | 36.6 | 37.7 |
| Gross Profit | 62.3 | 64.1 | 61.8 | 58.6 | 55.1 | 58.6 | 63.4 | 62.3 |
| R&D | 1.4 | 3.2 | 5.4 | 10.5 | 17.8 | 20.1 | 15.6 | 10.7 |
| SG&A | 47.2 | 42.2 | 49.8 | 76.0 | 73.9 | 71.4 | 64.3 | 56.8 |
| Operating Income | 6.7 | 2.5 | -5.2 | -29.9 | -38.6 | -36.0 | -19.2 | -7.2 |
| Income Tax | 1.5 | 0.6 | -0.1 | -7.7 | -7.2 | 13.9 | 0.0 | 0.1 |
| Net Income | 5.2 | 2.4 | -5.0 | -19.4 | -31.0 | -48.2 | -18.0 | -6.4 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on KRMD: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $41.1M 100.0% | $33.6M 100.0% | $28.5M 100.0% | $27.9M 100.0% | $23.5M 100.0% | $24.2M 100.0% | $23.2M 100.0% | $17.4M 100.0% | $12.3M 100.0% | $12.2M 100.0% |
| Cost of Revenue | $15.5M 37.7% | $12.3M 36.6% | $11.8M 41.4% | $12.5M 44.9% | $9.7M 41.4% | $9.2M 38.2% | $8.3M 35.9% | $6.5M 37.7% | $4.7M 38.4% | $4.6M 37.9% |
| Cost of Products | — | — | — | — | — | — | — | — | $4.7M 38.4% | $4.6M 37.9% |
| Gross Profit | $25.6M 62.3% | $21.3M 63.4% | $16.7M 58.6% | $15.4M 55.1% | $13.8M 58.6% | $14.9M 61.8% | $14.9M 64.1% | $10.8M 62.3% | $7.6M 61.6% | $7.6M 62.1% |
| Research & Development | $4.4M 10.7% | $5.3M 15.6% | $5.7M 20.1% | $5.0M 17.8% | $2.5M 10.5% | $1.3M 5.4% | $740K 3.2% | $241K 1.4% | $237K 1.9% | $207K 1.7% |
| Selling, General & Admin | $23.4M 56.8% | $21.6M 64.3% | $20.4M 71.4% | $20.6M 73.9% | $17.9M 76.0% | $12.0M 49.8% | $9.8M 42.2% | $8.2M 47.2% | $7.8M 63.2% | $5.9M 48.5% |
| Total Operating Expenses | $28.6M 69.5% | $27.8M 82.6% | $27.0M 94.6% | $26.1M 93.7% | $20.8M 88.5% | $16.2M 67.0% | $14.3M 61.6% | $9.6M 55.6% | $8.3M 67.6% | $6.4M 52.4% |
| Operating Income | -$3.0M -7.2% | -$6.4M -19.2% | -$10.3M -36.0% | -$10.8M -38.6% | -$7.0M -29.9% | -$1.3M -5.2% | $586K 2.5% | $1.2M 6.7% | -$736K -6.0% | $1.2M 9.6% |
| Interest Expense | — | — | — | — | — | — | — | — | $2K 0.0% | $3K 0.0% |
| Other Income (Expense), net | $356K 0.9% | $382K 1.1% | $496K 1.7% | $106K 0.4% | $665K 2.8% | $61K 0.3% | $111K 0.5% | $28K 0.2% | $3K 0.0% | -$9K -0.1% |
| Pretax Income | -$2.6M -6.4% | -$6.1M -18.0% | -$9.8M -34.3% | -$10.7M -38.3% | -$6.4M -27.1% | $1.2M 4.9% | $696K 3.0% | $1.2M 6.8% | -$777K -6.3% | $1.1M 9.3% |
| Income Tax Expense | $22K 0.1% | $3K 0.0% | $4.0M 13.9% | -$2.0M -7.2% | -$1.8M -7.7% | -$18K -0.1% | $132K 0.6% | $266K 1.5% | -$242K -2.0% | $360K 2.9% |
| Net Income | -$2.6M -6.4% | -$6.1M -18.0% | -$13.7M -48.2% | -$8.7M -31.0% | -$4.6M -19.4% | -$1.2M -5.0% | $564K 2.4% | $911K 5.2% | -$535K -4.4% | $783K 6.4% |
| Per Share | ||||||||||
| EPS (Basic) | $-0.06 | $-0.13 | $-0.30 | $-0.19 | $-0.10 | $-0.03 | $0.01 | $0.02 | $-0.01 | $0.02 |
| EPS (Diluted) | $-0.06 | $-0.13 | $-0.30 | $-0.19 | $-0.10 | $-0.03 | $0.01 | $0.02 | $-0.01 | $0.02 |
| Weighted Avg Shares (Basic) | 46.2M | 45.8M | 45.6M | 45.0M | 44.4M | 41.9M | 38.8M | 38.1M | 37.8M | 38.0M |
| Weighted Avg Shares (Diluted) | 46.2M | 45.8M | 45.6M | 45.0M | 44.4M | 41.9M | 39.1M | 38.9M | 37.9M | 38.0M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| KRMD | $149M | — | — | 3.6× | 22.2% | 62.3% | -6.4% | -15.5% | -15.5% | — | 86 |
Peers = companies sharing KRMD's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position